Which has the lower trailing P/E, DOCS or KNSA?

DOCS has the lower trailing P/E: DOCS trades at 33.68 and KNSA at 75.60. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, DOCS or KNSA?

Over the past five years, KNSA grew revenue faster — DOCS at a 21.94% CAGR versus KNSA at 155.66%.

Is DOCS or KNSA more profitable?

DOCS runs the higher net margin — DOCS at 25.48% versus KNSA at 9.59%.

How have DOCS and KNSA total returns compared?

Over the past 5 years, DOCS delivered -18.23% and KNSA delivered 47.48% annualized total return. Past performance doesn't predict future results.

Doximity, Inc. (DOCS) vs Kiniksa Pharmaceuticals International, plc (KNSA)

A side-by-side comparison of Doximity, Inc. and Kiniksa Pharmaceuticals International, plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

DOCS

Doximity, Inc.

$5.35B

$28.63HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

KNSA

Kiniksa Pharmaceuticals International, plc

$5.65B

$74.09HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — DOCS vs KNSA

growth of $100 · dividends reinvested · last 5y

DOCS -46.1% (-11.6%/yr)KNSA +434.0% (+39.8%/yr)KNSA compounded faster over this window

Log scale — wide-divergence pair

DOCS KNSA

DOCS vs KNSA: by the numbers

•KNSA is the larger company ($5.65B vs $5.35B market cap).
•DOCS trades at the lower trailing earnings multiple (33.68 vs 75.60 P/E), one valuation lens rather than an overall verdict.
•DOCS converts more revenue to profit (25.48% vs 9.59% net margin).
•KNSA grew revenue faster over the past five years (155.66% vs 21.94% CAGR).

Metrics side by side

Valuation

Metric	DOCS	KNSA
P/E ratio	33.68	75.60
Forward P/E	21.25	53.20
PEG ratio	0.65	N/A
P/S ratio	8.17	6.71
P/B ratio	5.85	8.63
EV / EBITDA	24.06	53.70
FCF yield	5.59%	3.24%

Profitability

Metric	DOCS	KNSA
Gross margin	88.07%	54.49%
Operating margin	29.60%	11.92%
Net margin	25.48%	9.59%
ROE	18.24%	12.33%
ROIC	15.35%	9.76%

Growth (annualized)

Metric	DOCS	KNSA
Revenue CAGR (5Y)	21.94%	155.66%
EPS CAGR (5Y)	54.32%	N/A
FCF CAGR (5Y)	23.75%	N/A
Total return CAGR (5Y)	-18.23%	47.48%

Frequently asked

Which has the lower trailing P/E, DOCS or KNSA?: DOCS has the lower trailing P/E: DOCS trades at 33.68 and KNSA at 75.60. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, DOCS or KNSA?: Over the past five years, KNSA grew revenue faster — DOCS at a 21.94% CAGR versus KNSA at 155.66%.
Is DOCS or KNSA more profitable?: DOCS runs the higher net margin — DOCS at 25.48% versus KNSA at 9.59%.
How have DOCS and KNSA total returns compared?: Over the past 5 years, DOCS delivered -18.23% and KNSA delivered 47.48% annualized total return. Past performance doesn't predict future results.

Go deeper

Full DOCS analysis Full KNSA analysis Interactive comparison tool

Dig into the metrics

Doximity P/E ratio Kiniksa Pharmaceuticals International P/E ratio Doximity ROE Kiniksa Pharmaceuticals International ROE Doximity operating margin Kiniksa Pharmaceuticals International operating margin Doximity revenue growth Kiniksa Pharmaceuticals International revenue growth Doximity free cash flow Kiniksa Pharmaceuticals International free cash flow

Doximity & Kiniksa Pharmaceuticals International appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.